arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

Propanc Biopharma, Inc.

PPCB
$1.20 ▼ -0.17 (-12.41%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
18 Visible periods
23 Metrics
Peer-ranked Benchmarks
Price Chart
38
Health
Weak
Bullish
auto_awesome

Analytical Summary

Propanc Biopharma, Inc. shows strong fundamentals with top-quartile Debt to Equity. The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $4.8M
Dividend Yield
Revenue Growth
Op. Margin
ROIC -313.3%
FCF / Share $-0.10
Trailing P/E
Price / Book 1.0x
FCF Yield
Debt / Equity 0.04
info Valuation on last close. End-of-day price, Aug 7, 2026.

18-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Net Income Profit after all expenses
$-58.92M
↓ -3136.6%
FCF / Share Free cash flow per share
$-0.10
↑ +83.9%
Long-Term Debt Long-term obligations
$537.92K
↑ +34.7%
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Financial Health
46
Cash Quality
22

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 18 years · 64 quarters